Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials

Stroke

Volumn 30, Issue 6, 1999, Pages 1223-1229

  Hart, Robert G ^a   Pearce, Lesly A ^b   McBride, Ruth ^b   Rothbart, Robert M ^c   Asinger, Richard W ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Stat and Epidemiol Res Corp   (United States)

^c LeBauer Cardiology Associates   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Cerebral embolism; Estrogens; Risk factors; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ESTROGEN; WARFARIN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; GENDER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK;

EID: 0033063754     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.6.1223     Document Type: Article

References (44)

1. Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in nonvalvular atrial fibrillation. Neurology. 1998;51:674-681.
2. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
3. Stroke Prevention in Atrial Fibrillation Investigators. Prospective identification of patients with nonvalvular atrial fibrillation at low-risk of stroke during treatment with aspirin. JAMA. 1998;279:1273-1277.
4. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med. 1992;116:1-5.
5. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: echocardiographic features of patients at risk. Ann Intern Med. 1992;116:6-12.
6. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995:5:147-157.
7. European Atrial Fibrillation Trialists' Study Group. Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attacks or minor ischemic stroke. Lancet. 1993; 342:1255-1262.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized clinical trials. Arch Intern Med. 1994;154:1949-1957.
9. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84: 527-539.
10. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin vs. aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
11. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin compared to aspirin for prevention of arterial thromboembolism in atrial fibrillation: design and patient characteristics of the SPAF II Study. Cerebrovasc Dis. 1992;2:332-341.
12. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation III study: rationale, design and patient features. J Stroke Cerebrovasc Dis. 1997;5:341-353.
13. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
14. Hart RG. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation. Ann Intern Med. 1998;128:408. Comment.
15. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology. 1993;43:32-36.
16. Blackshear JL, Pearce LA, Asinger RW, Dittrich HC, Goldman ME, Zabalgoitia M, Rothbart RM, Halperin JL. Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with non-rheumatic atrial fibrillation. Am J Cardiol. 1993;72:840-843.
17. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G. Mini-dose warfarin and aspirin in atrial fibrillation: the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-1521.
18. Hellemons BSP, Langenberg M, Lodder J, Vermeer F, Schouten HJA, van Ree JW, Knottnerus JA. Primary prevention of arterial thromboembolism in patients with non-rheumatic atrial fibrillation in general practice. Cerebrovasc Dis. 1997;7(suppl IV):11. Abstract.
19. Feinberg WM, Kronmal RA, Newman AB, Kraut MA, Bovill EG, Cooper L, Hart RG. Stroke risk in an elderly population with atrial fibrillation. J Gen Intern Med. 1999;14:56-59.
20. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulation in the community Lancet. 1998;352:1167-1171.
21. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Arch Intern Med. 1997;157:1237-1240.
22. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;280: 1930-1935.
23. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1,066 patients from three clinical trials. Arch Intern Med. 1998;158:1316-1320.
24. Yoshida M, Nakamura Y, Higashikawa M, Kinoshita M. Predictors of ischemic stroke in non-rheumatic atrial fibrillation. Int J Cardiol. 1996; 56:61-70.
25. Stollberger C, Chnupa P, Kronik G, Brainin M, Finsterer J, Schneider B, Slany J. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med. 1998;128:630-638.
26. Meade TW. Hormone replacement therapy and haemostatic function. Thromb Haemost. 1997;78:765-769.
27. Petitti DB, Sidney S, Quesenberry CP, Bernstein A. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy. Stroke. 1998;29:23-28.
28. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke: follow-up of a population-based cohort in Sweden. Arch Intern Med 1993;153: 1201-1209.
29. Psaty BM, Heckbert SR, Atkins D. A review of the association of estrogens and progestins with cardiovascular disease in post menopausal women. Arch Intern Med. 1993;153:1421-1427.
30. Pedersen AT, Lindegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet. 1997;350:1277-1283.
31. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FF, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the Nurse's Health Study. N Engl J Med. 1991;325:756-762.
32. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal estrogen treatment and stroke: a prospective study. BMJ. 1988;297:519-522.
33. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the HERS Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in Postmenopausal women. JAMA. 1998;280:605-613.
34. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-980.
35. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of post-menopausal oestrogens. Lancet. 1996;348:981-983.
36. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348: 983-987.
37. Gutthann S, Rodriguez L, Castellsague J, Ollart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997;314:796-800.
38. Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) trial. JAMA. 1995;273:199-208.
39. Pahor M, Guralnik JM, Havlik RJ, Carbonin P, Salive ME, Ferrucci L, Corti MC, Hennekens CH. Alcohol consumption and risk of deep venous thrombosis and pulmonary embolism in older persons. J Am Geriatr Soc. 1996;44:1030-1037.
40. Flegel KM, Hanley J. Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation. Stroke. 1989;20: 1000-1004.
41. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation. Am J Med. 1991;91:156-161.
42. Hart RG, Pearce LA, Halperin JL, Miller VT. Aspirin in elderly patients with atrial fibrillation. Stroke. 1994;25:1525-1526. Abstract.
43. Stroke Prevention in Atrial Fibrillation Investigators. A differential effect of aspirin for the prevention of stroke in atrial fibrillation. J Stroke Cerebrovasc Dis. 1993;3:181-188.
44. Miller VT, Pearce LA, Feinberg WM, Rothrock JF, Anderson DC, Hart RG. Differential effect of aspirin vs. warfarin on clinical stroke subtypes in patients with atrial fibrillation. Neurology. 1996;46:238-240.